2. Anti-infection Apoptosis Epigenetics Cell Cycle/DNA Damage Immunology/Inflammation
  3. SARS-CoV Caspase PARP Pyroptosis Interleukin Related IFNAR
  4. IRF1-IN-1

IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor. IRF1-IN-1 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-1 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1). IRF1-IN-1 has a protective effect on ionizing radiation-induced inflammatory skin injury.

For research use only. We do not sell to patients.

IRF1-IN-1 Chemical Structure

IRF1-IN-1 Chemical Structure

CAS No. : 701225-07-2

Size Price Stock Quantity
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

IRF1-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor. IRF1-IN-1 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-1 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1). IRF1-IN-1 has a protective effect on ionizing radiation-induced inflammatory skin injury[1].

IC50 & Target[1]

PARP-1

 

IL-1

 

Caspase-1

 

In Vitro

IRF1-IN-1 pretreatment (20 μM, 12 h) decreases the recruitment of IRF1 to the promoter of CASP1 in irradiated HaCaT cells (20 Gy)[1].
IRF1-IN-1 (20 μM, 24 h) attenuates the NSP-10 plasmid transfection-induced IRF1 activation in HELF, HaCaT and WS1 cells[1].
IRF1-IN-1 (50  μM, 24  h) treatment reduces the transcriptional activity of IRF1 in HELF cells 96 h after SARS-CoV-2 pseudovirus infection[1].
IRF1-IN-1 decreases radiation (20 Gy)-induced cell death in K150 cells[1].
IRF1-IN-1 maintains mitochondrial activity and ROS production in skin cells in the early stage after irradiation[1].
IRF1-IN-1 significantly inhibits the cell death signaling pathway, i.e., suppresses cleavage of Caspase 1, GSDMD, IL-1 and PARP1[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IRF1-IN-1 Related Antibodies
In Vivo

IRF1-IN-1 pretreatment (100 μg/d, s.c., one every other day before irradiation) has a potential protective effect in 35 Gy radiation-induced inflammatory skin injury mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Radiogenic skin injury mice (intraperitoneal injection of pentobarbital sodium (1%, 30 mg/kg), 35 Gy at the dose rate of 1000 cGy/min by a 6-MeV electron beam)[1]
Dosage: 100 μg/d
Administration: Subcutaneous injection (s.c.), one every other day before irradiation, pretreatment
Result: Showed a significant reduction in acute skin inflammatory manifestations, such as erythema and exudation and accelerated the healing process.
Showed protective effects on the function and structural integrity of radiation-induced lesions to the claws.
Molecular Weight

440.52

Formula

C22H24N4O4S
CAS No.
Appearance

Solid

SMILES

O=C1C2=C(N=CN1CCC(NC3=CC=C(S(=O)(N4CCCCC4)=O)C=C3)=O)C=CC=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 83.33 mg/mL (189.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2700 mL 11.3502 mL 22.7004 mL
5 mM 0.4540 mL 2.2700 mL 4.5401 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2700 mL 11.3502 mL 22.7004 mL 56.7511 mL
5 mM 0.4540 mL 2.2700 mL 4.5401 mL 11.3502 mL
10 mM 0.2270 mL 1.1350 mL 2.2700 mL 5.6751 mL
15 mM 0.1513 mL 0.7567 mL 1.5134 mL 3.7834 mL
20 mM 0.1135 mL 0.5675 mL 1.1350 mL 2.8376 mL
25 mM 0.0908 mL 0.4540 mL 0.9080 mL 2.2700 mL
30 mM 0.0757 mL 0.3783 mL 0.7567 mL 1.8917 mL
40 mM 0.0568 mL 0.2838 mL 0.5675 mL 1.4188 mL
50 mM 0.0454 mL 0.2270 mL 0.4540 mL 1.1350 mL
60 mM 0.0378 mL 0.1892 mL 0.3783 mL 0.9459 mL
80 mM 0.0284 mL 0.1419 mL 0.2838 mL 0.7094 mL
100 mM 0.0227 mL 0.1135 mL 0.2270 mL 0.5675 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IRF1-IN-1 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IRF1-IN-1701225-07-2SARS-CoVCaspasePARPPyroptosisInterleukin RelatedIFNARSARS coronaviruspoly ADP ribose polymerase ILInterferon-α/β receptorInterferon-alpha/beta receptorRadiationHELFHaCaTWS1Skin injuryErythemaNSP-10Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IRF1-IN-1
Cat. No.:
HY-171006
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.